keyword
https://read.qxmd.com/read/38401406/residual-effects-of-medications-for-sleep-disorders-on-driving-performance-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials-nma-driving-and-hypnotics
#1
JOURNAL ARTICLE
Michele Fornaro, Claudio Caiazza, Flavia Rossano, Flavia Cilmi, Michele De Prisco, Eduard Vieta, Trevor Thompson, Marco Solmi, Andre Ferrer Carvalho, Felice Iasevoli, Andrea de Bartolomeis
Sleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized Mean Difference/SMD) and driving impairment rates on the first morning (co-primary outcomes) and endpoint...
February 23, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38380193/dolichocephaly-arachnodactyly-diplopia-and-distal-myopathy-novel-phenotype-of-micu1-variant-c-553c-t
#2
Josef Finsterer, Awini Barwari
Pathogenic variants in mitochondrial calcium uptake 1 ( MICU1)  manifest phenotypically heterogeneously but most frequently in the brain and skeletal muscle. Dolichocephaly, arachnodactyly, diplopia, and distal myopathy have not been reported in carriers of a pathogenic  MICU1  variant. The patient is a 23-year-old female with consanguineous parents (first cousins) who was a carrier of the homozygous  MICU1  variant c.553C>T, phenotypically presenting with developmental delay, intellectual disability, ataxia, dysmorphia (dolichocephaly, arachnodactyly, clinodactyly, hypertelorism, wide nasal bridge), myopathy (ptosis, double vision, strabismus, distal limb weakness, diffuse wasting, hypotonia), hyperextensible joints and hyperkyphosis...
January 2024: Curēus
https://read.qxmd.com/read/38315683/efficacy-and-safety-of-eszopiclone-combined-with-drug-therapy-in-the-treatment-of-insomnia-after-stroke-a-network-meta-analysis-and-systematic-review
#3
JOURNAL ARTICLE
Ruo-Yang Li, De-Liang Zhu, Ke-Yu Chen
OBJECTIVE: To evaluate the efficacy and safety of multi-drug therapy based on eszopiclone in the treatment of insomnia after stroke using a network meta-analysis method and to provide evidence for clinical practice. METHOD: Computer searches of PubMed, Excerpt Medica Database (Embase), Cochrane Library Central Register of Controlled Trials, APA PsycInfo, CNKI, WanFang, Sinomed and other databases were performed to search for clinical randomized controlled studies (RCTs) on multi-drug therapy based on eszopiclone in the treatment of insomnia patients after stroke...
2024: PloS One
https://read.qxmd.com/read/38268137/sleep-medicines-are-often-prescribed-for-older-adults-%C3%A2-75%C3%A2-years-without-appropriate-dosing-instructions-a-nationwide-retrospective-register-study-in-finland
#4
JOURNAL ARTICLE
Sini-Tuulia Eronen, Terhi Kurko, Sirkka-Liisa Kivelä, Tiina Paunio, Marja Airaksinen, Tomi Rantamäki
BACKGROUND: Sleep medicines should be prescribed cautiously, accompanied by instructions that ensure appropriate use and reduce risks. This is especially important for older adults, for whom many of these medicines are classified as potentially inappropriate medicines. METHODS: We investigated the use and appropriateness of dosing instructions for sleep medicines (described in the Finnish National Current Care Guideline for Insomnia) prescribed for older adults (≥75 years) and dispensed with instruction label in pharmacies...
January 24, 2024: Acta Psychiatrica Scandinavica
https://read.qxmd.com/read/38022834/optimizing-treatment-for-older-adults-with-depression
#5
REVIEW
Maytinee Srifuengfung, Bethany R Tellor Pennington, Eric J Lenze
This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants but also addressing the concurrent use of inappropriate medications, many of which have cognitive side effects...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37801864/associations-between-insomnia-medications-and-risk-of-death-by-suicide
#6
JOURNAL ARTICLE
Jill E Lavigne, Kwan Hur, Jason B Gibbons, Wilfred R Pigeon
PURPOSE: Insomnia is a modifiable risk factor for suicide often treated with medications. However, little is known about the associations between insomnia medications and risk of death by suicide. The purpose of this study is to model the comparative risk of suicide by each insomnia medication compared to zolpidem, a sedative-hypnotic approved for insomnia. METHODS: First prescription fills of medications commonly used to treat insomnia were identified in electronic medical records...
November 2023: Sleep Medicine
https://read.qxmd.com/read/37736438/mirtazapine-a-one-stop-strategy-for-treatment-of-opioid-withdrawal-symptoms
#7
REVIEW
Elisha Lalani, Raakhi Menon, Mariam A Mufti, Cecil Kumfa, Mukaila Raji
Public health efforts to reduce the opioid overdose epidemic and treat opioid use disorder (OUD) have met with challenges associated with current non-standardized approaches to managing opioid withdrawal symptoms, such as itching, jitteriness, anxiety, depression, craving, vomiting, diarrhea, insomnia, and anorexia. These symptoms pose substantial obstacles to the safe initiation of medications for OUD, maintenance of long-term sobriety, and prevention of relapse. In clinical practice, multiple medications (polypharmacy) are prescribed to manage these withdrawal symptoms, including ondansetron and promethazine for vomiting and nausea, loperamide and Lomotil for diarrhea, hydroxyzine and doxepin for pruritus, benzodiazepines, the Z-drugs, and melatonin for insomnia, and benzos, tricyclic antidepressants (TCAs), and various serotonergic agents for anxiety...
August 2023: Curēus
https://read.qxmd.com/read/37700038/usefulness-of-mirtazapine-and-ssris-in-late-life-depression-post-hoc-analysis-of-the-gundam-study
#8
JOURNAL ARTICLE
Masaki Kato, Hajime Baba, Yoshiteru Takekita, Minami Naito, Yosuke Koshikawa, Hiroki Bandou, Toshihiko Kinoshita
OBJECTIVE: Mirtazapine and SSRIs are widely prescribed as first-line agents for late-life depression. However, evidence for these drugs is mostly based on non-elderly patients. Therefore, we reanalyzed a randomized controlled trial of mirtazapine versus SSRIs for depression in a sub-population of late-life patients. METHODS: A randomized controlled trial was conducted with 141 patients, of whom 41 were elderly, and 100 were non-elderly. This study compared SSRIs and mirtazapine in late-life depression, examined late-onset and early adult-onset separately and compared elderly and non-elderly patients for each drug...
September 13, 2023: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/37243798/switching-to-lemborexant-for-the-management-of-insomnia-in-mental-disorders-the-slim-study
#9
JOURNAL ARTICLE
Sho Horikoshi, Itaru Miura, Yuhei Suzuki, Yuri Kobayashi, Yoichiro Hirata, Masayuki Goto, Mizue Ichinose, Shinnosuke Yamamoto, Keiko Kanno-Nozakio, Kenya Watanabe, Hirooki Yabe
STUDY OBJECTIVES: We conducted a retrospective study to investigate the efficacy and safety of switching from other hypnotics, including benzodiazepines, Z-drugs (BZDs), suvorexant, ramelteon, mirtazapine, trazodone, and antipsychotics to lemborexant (LEB), a dual orexin receptor antagonist, for 3 months (3M). METHODS: Clinical data obtained from the medical records of 61 patients treated at the Horikoshi Psychosomatic Clinic between December 2020 and February 2022 were analyzed, including the Athens Insomnia Scale (AIS), Epworth Sleepiness Scale (ESS), and Perceived Deficits Questionnaire-5 (PDQ-5)...
May 30, 2023: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://read.qxmd.com/read/37194534/-antidepressants
#10
JOURNAL ARTICLE
Koichiro Watanabe
Tricyclic antidepressants possess anticholinergic, alpha 1 anti-adrenergic, and H1 antihistaminic properties, and an overdose affects patients' quality of life, which has led to the development of novel antidepressant drugs. Selective serotonin reuptake inhibitors (SSRIs) are non-sedating drugs that selectively reuptake serotonin and are effective against anxiety. Adverse effects of SSRIs include gastrointestinal disturbances, sexual dysfunction, and bleeding tendency. Serotonin noradrenaline reuptake inhibitors (SNRIs) are non-sedating agents that are expected to improve volition...
May 2023: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://read.qxmd.com/read/37057036/occurrence-of-terrifying-nightmares-after-few-days-of-mirtazapine-use-in-elderly-patients
#11
Liliana Dell'Osso, Primo Lorenzi, Benedetta Nardi, Barbara Carpita, Francesca Benedetti, Ivan Mirko Cremone
Introduction . Sleep disturbance and insomnia are some of the most frequent complaints in patients suffering from depression. Some common antidepressant with excitatory effects may worsen sleep qualities, whereas others (like mirtazapine), thanks to their antihistaminergic action, are associated with sedative properties and can quickly improve sleep quality. In the case of mirtazapine, even if its mechanisms of action on sleep remain controversial, beneficial changes in sleep pattern may be observable since the first dose and are associated with a faster onset of the antidepressive action...
2023: Case Reports in Psychiatry
https://read.qxmd.com/read/37055872/mirtazapine-induced-neutropenic-sepsis-in-an-older-person-a-case-report
#12
JOURNAL ARTICLE
Alice Maidwell-Smith, Charlotte Kirk
BACKGROUND: Mirtazapine is a frequently prescribed psychotropic drug for depression in older age. It is considered safe and has a side-effect profile uniquely favorable to an older person affected by reduced appetite, difficulty maintaining body weight, or insomnia. However, it is largely unknown that mirtazapine can cause a dangerous decline in neutrophil count. CASE PRESENTATION: We present a case of mirtazapine-induced severe neutropenia in a 91-year-old white British woman requiring drug withdrawal and granulocyte-colony stimulating factor administration...
April 14, 2023: Journal of Medical Case Reports
https://read.qxmd.com/read/37054418/top-20-research-studies-of-2022-for-primary-care-physicians
#13
JOURNAL ARTICLE
Roland Grad, Mark H Ebell
This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19. Statins for primary prevention of cardiovascular disease produce only a small absolute reduction in a person's likelihood of dying (0.6%), having a myocardial infarction (0.7%), or having a stroke (0.3%) over three to six years. Supplemental vitamin D does not reduce the risk of a fragility fracture, even in people with low baseline vitamin D levels or a previous fracture...
April 2023: American Family Physician
https://read.qxmd.com/read/37032615/a-9-year-old-female-with-iron-deficiency-has-severe-periodic-limb-movements-while-taking-mirtazapine-for-insomnia
#14
Melody Hawkins
UNLABELLED: Mirtazapine is a Food and Drug Administration-approved atypical antidepressant used off-label for insomnia. Mirtazapine has been associated with movement disorders in adults. A 9-year-old female was seen in the sleep clinic for symptoms of insomnia, nocturnal awakenings, restless sleep, and growing pains. Mirtazapine was started prior to presentation for severe insomnia. A sleep study showed frequent repetitive leg movements prior to sleep onset as well as significant periodic limb movement disorder with a periodic limb movement index of 25...
July 1, 2023: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://read.qxmd.com/read/37029641/-prescribing-trends-of-benzodiazepine-and-other-sedatives-in-the-lisbon-and-tagus-valley-regional-health-administration-between-2013-and-2020-a-retrospective-study
#15
JOURNAL ARTICLE
Samuel Gomes, Paula Broeiro-Gonçalves, Cristina Meireles, Daniel Caldeira, João Costa, Mara Pereira Guerreiro, Nadine Ribeiro, Renata Afonso
INTRODUCTION: Among the Organization for Economic Co-operation and Development members, Portugal has the highest reported consumption of anxiolytics, hypnotics, and sedatives, of which a large proportion are benzodiazepines or related drugs. These are known to cause tolerance and dependence. Other drugs with hypnotic effect, such as antidepressants, antihistamines, antipsychotics, or anticonvulsants have been identified by some reports as alternatives to benzodiazepines for the treatment of insomnia...
April 3, 2023: Acta Médica Portuguesa
https://read.qxmd.com/read/36970994/benzodiazepine-z-drug-and-sleep-medication-prescriptions-in-male-and-female-people-with-opioid-use-disorder-on-buprenorphine-and-comorbid-insomnia-an-analysis-of-multi-state-insurance-claims
#16
JOURNAL ARTICLE
Caitlin E Martin, Hetal Patel, Joseph M Dzierewski, F Gerard Moeller, Laura J Bierut, Richard A Grucza, Kevin Y Xu
STUDY OBJECTIVES: In adult populations, women are more likely than men to be prescribed benzodiazepines. However, such disparities have not been investigated in people with opioid use disorder (OUD) and insomnia receiving buprenorphine, a population with particularly high sedative/hypnotic receipt. This retrospective cohort study used administrative claims data from Merative™ MarketScan® Commercial and Multi-State Medicaid Databases (2006-2016) to investigate sex differences in the receipt of insomnia medication prescriptions among patients in OUD treatment with buprenorphine...
March 27, 2023: Sleep
https://read.qxmd.com/read/36897604/in-brief-off-label-amitriptyline-for-insomnia
#17
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 20, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36724694/initial-antidepressant-choice-by-non-psychiatrists-learning-from-large-scale-electronic-health-records
#18
JOURNAL ARTICLE
Yi-Han Sheu, Colin Magdamo, Matthew Miller, Jordan W Smoller, Deborah Blacker
OBJECTIVES: Pharmacological treatment of depression mostly occurs in non-psychiatric settings, but the determinants of initial choice of antidepressant treatment in these settings are unclear. We investigate how non-psychiatrists choose among four antidepressant classes at first prescription (selective serotonin reuptake inhibitors [SSRI], bupropion, mirtazapine, or serotonin-norepinephrine reuptake inhibitors [SNRI]). METHOD: Using electronic health records (EHRs), we included adult patients at the time of first antidepressant prescription with a co-occurring diagnosis code for a depressive disorder...
2023: General Hospital Psychiatry
https://read.qxmd.com/read/36630579/drugs-for-chronic-insomnia
#19
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 9, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36114064/mirtazapine-associated-acute-pancreatitis-in-a-patient-with-insomnia-and-co-occurring-psychiatric-disorders
#20
Sean He, Taylor P Ikner, Brittany V Taylor, Taylor Aguiar, Nina P Thakur, Subhajit Chakravorty
We report the case of an African American patient who developed drug-associated acute pancreatitis without hypertriglyceridemia, after being treated with mirtazapine for major depressive disorder (MDD). Acute pancreatitis is characterized by rapid inflammation and autodigestion of the pancreas, which may become life-threatening. Although heavy alcohol use and gallstones are the most common causes of acute pancreatitis, some medications are also known to cause drug-induced acute pancreatitis. This report describes a 47-year-old African American female with a history of MDD, insomnia, posttraumatic stress disorder (PTSD), and alcohol use disorder, who was prescribed mirtazapine...
September 13, 2022: Journal of the National Medical Association
keyword
keyword
162222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.